[go: up one dir, main page]

MX2009009700A - Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso. - Google Patents

Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.

Info

Publication number
MX2009009700A
MX2009009700A MX2009009700A MX2009009700A MX2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A MX 2009009700 A MX2009009700 A MX 2009009700A
Authority
MX
Mexico
Prior art keywords
chemotherapy
hla class
remedy
active ingredient
diabody
Prior art date
Application number
MX2009009700A
Other languages
English (en)
Inventor
Toshio Matsumoto
Shuji Ozaki
Masahiro Abe
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39759531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2009009700A publication Critical patent/MX2009009700A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se ha aclarado que la actividad citotóxica del diacuerpo C3B3 es inducida con menor concentración en líneas celulares de tumor hematológico resistentes a agentes quimioterapéuticos que sobreexpresan proteínas MDR1 y HLA clase lA, que en la cepa originaria. También se halló que cuando la línea celular de tumor hematológico resistente a agentes quimioterapéuticos se trata previamente con un diacuerpo C3B3, la actividad citotóxica del fármaco quimioterapéutico solo aumenta y el fármaco es incorporado en una mayor cantidad en las células. Más específicamente, se descubrió que el diacuerpo C3B3 ejerce una actividad antitumoral sobre las células tumorales que expresan MDR1 que sobreexpresan HLA de clase I, y tiene un efecto para superar la resistencia al fármaco.
MX2009009700A 2007-03-12 2008-03-12 Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso. MX2009009700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007062339 2007-03-12
PCT/JP2008/054443 WO2008111597A1 (ja) 2007-03-12 2008-03-12 Hlaクラスiを認識する抗体を有効成分として含有する化学療法剤耐性癌治療剤、およびその利用

Publications (1)

Publication Number Publication Date
MX2009009700A true MX2009009700A (es) 2009-10-07

Family

ID=39759531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009700A MX2009009700A (es) 2007-03-12 2008-03-12 Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.

Country Status (15)

Country Link
US (1) US20100092461A1 (es)
EP (1) EP2133093A1 (es)
JP (1) JPWO2008111597A1 (es)
KR (1) KR20090119992A (es)
CN (1) CN101687034A (es)
AR (1) AR066690A1 (es)
AU (1) AU2008225478A1 (es)
BR (1) BRPI0808731A2 (es)
CA (1) CA2680280A1 (es)
CL (1) CL2008000719A1 (es)
IL (1) IL200375A0 (es)
MX (1) MX2009009700A (es)
PE (1) PE20081881A1 (es)
TW (1) TW200846372A (es)
WO (1) WO2008111597A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2004033499A1 (ja) * 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
WO2005056603A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
JPWO2006123724A1 (ja) * 2005-05-18 2008-12-25 国立大学法人徳島大学 抗ｈｌａ抗体を利用した新規医薬品
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
EP1908482B1 (en) * 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
TW200808351A (en) * 2006-07-13 2008-02-16 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
US20150079093A1 (en) * 2012-01-13 2015-03-19 Julus-Maximilians-Universität Würzburg Dual antigen-induced bipartite functional complementation
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
US20230066830A1 (en) * 2019-12-20 2023-03-02 Virginia Commonwealth University Methods and compositions for inducing apoptosis in cancer stem cells

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5077216A (en) * 1988-07-06 1991-12-31 The Trustees Of Dartmouth College Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5223241A (en) * 1990-10-01 1993-06-29 The General Hospital Corporation Method for early detection of allograft rejection
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994009817A1 (en) * 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
EP0672142B1 (en) * 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
EP0628078B1 (en) * 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
SK281964B6 (sk) * 1993-09-03 2001-09-11 Chugai Seiyaku Kabushiki Kaisha Monoklonálna protilátka schopná vyvolať apoptózu myeloidných buniek, jej fragmenty a hybridóm
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
US6719972B1 (en) * 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
ATE306930T1 (de) * 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5690935A (en) * 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
CN1097438C (zh) * 1995-02-28 2003-01-01 普罗格特-甘布尔公司 微生物稳定的非充气饮料产品的制备
WO1996030394A1 (en) 1995-03-31 1996-10-03 Jakob Bohr Method for protein folding
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
EP2258726A1 (en) * 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US20020193571A1 (en) * 1996-01-08 2002-12-19 Paul J. Carter Wsx receptor agonist antibodies
FR2745008A1 (fr) * 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
AU2232597A (en) * 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
ATE316792T1 (de) * 1996-05-09 2006-02-15 Pharma Pacific Pty Ltd Stimulierung wirtseigener abwehrmechanismen gegen krebs
US6323000B2 (en) * 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO1999002567A2 (en) * 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US7531643B2 (en) * 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
EP1035132B1 (en) * 1997-09-11 2008-05-14 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US5998593A (en) * 1998-03-10 1999-12-07 Abbott Laboratories Fluorescent enzyme substrates
US7081360B2 (en) * 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US7696325B2 (en) * 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20040058393A1 (en) * 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
CA2426621A1 (en) * 2000-10-03 2003-04-01 Banyu Pharmaceutical Co., Ltd. Drug resistance-associated gene and use thereof
KR100870123B1 (ko) * 2000-10-20 2008-11-25 츄가이 세이야꾸 가부시키가이샤 저분자화 아고니스트 항체
ATE391174T1 (de) * 2000-10-20 2008-04-15 Chugai Pharmaceutical Co Ltd Modifizierter tpo-agonisten antikörper
EP1490483B1 (en) * 2001-04-19 2015-06-03 The Scripps Research Institute In vivo incorporation of unnatural amino acids
EP1369431A4 (en) * 2001-10-15 2005-01-12 Kirin Brewery ANTI-HLA-DR ANTIBODIES
MXPA04003535A (es) * 2001-10-15 2005-06-20 Immunomedics Inc Proteinas de enlace para objetivos directos.
WO2003068259A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
US20050130224A1 (en) * 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
US7098016B2 (en) * 2002-06-14 2006-08-29 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
WO2003105782A2 (en) * 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
WO2004003198A1 (ja) * 2002-06-27 2004-01-08 Genox Research, Inc. アレルギー性疾患の検査方法、および治療のための薬剤
JPWO2004033499A1 (ja) 2002-10-11 2006-02-09 中外製薬株式会社 細胞死誘導剤
JPWO2004037293A1 (ja) * 2002-10-22 2006-02-23 大日本住友製薬株式会社 安定化組成物
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
ATE545658T1 (de) * 2003-07-11 2012-03-15 Oncotherapy Science Inc Verfahren zur behandlung von synovialsarkom
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
EP1710255A4 (en) * 2003-12-12 2008-09-24 Chugai Pharmaceutical Co Ltd MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
TW200530266A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
WO2005056603A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
US20080274110A1 (en) * 2004-04-09 2008-11-06 Shuji Ozaki Cell Death-Inducing Agents
JP4700970B2 (ja) 2005-01-14 2011-06-15 鬼怒川ゴム工業株式会社 ドアグラスランの取付構造
US9493569B2 (en) * 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
JPWO2006123724A1 (ja) 2005-05-18 2008-12-25 国立大学法人徳島大学 抗ｈｌａ抗体を利用した新規医薬品
EP1908482B1 (en) * 2005-06-10 2017-09-06 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
TW200718780A (en) * 2005-06-10 2007-05-16 Chugai Pharmaceutical Co Ltd Sc(Fv)2 site-directed mutant
US7827400B2 (en) * 2005-07-28 2010-11-02 The Boeing Company Security certificate management
TW200808351A (en) * 2006-07-13 2008-02-16 Chugai Pharmaceutical Co Ltd Cell death-inducing agents
EP3111955B1 (en) * 2006-08-14 2019-01-23 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibody

Also Published As

Publication number Publication date
KR20090119992A (ko) 2009-11-23
BRPI0808731A2 (pt) 2013-08-06
EP2133093A1 (en) 2009-12-16
CN101687034A (zh) 2010-03-31
CA2680280A1 (en) 2008-09-18
AR066690A1 (es) 2009-09-09
PE20081881A1 (es) 2009-02-18
AU2008225478A1 (en) 2008-09-18
JPWO2008111597A1 (ja) 2010-06-24
IL200375A0 (en) 2010-04-29
WO2008111597A1 (ja) 2008-09-18
CL2008000719A1 (es) 2008-09-05
US20100092461A1 (en) 2010-04-15
TW200846372A (en) 2008-12-01

Similar Documents

Publication Publication Date Title
MX2009009700A (es) Agente terapeutico contra el cancer resistente a la quimioterapia que contiene anticuerpo reconocedor de hla clase i como ingrediente activo y su uso.
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
WO2011143318A3 (en) Anti-fgfr2 antibodies
EA201070463A1 (ru) Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство
EP4303236A3 (en) Cytotoxicity-inducing therapeutic agent
MX2015000428A (es) Composiciones y metodos para regular celulas t car.
WO2010036918A3 (en) Intracellular dna receptor
NZ711695A (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
GB2471588A (en) Therapeutic peptidomimetic macrocycles
WO2010085665A3 (en) Targeted delivery system
HK1201462A1 (en) Methods of treating cancer
WO2010145849A3 (en) Drug delivery systems
IL200517A0 (en) Agent for use in the case of fructose intolerance
WO2014062228A8 (en) An improved nanovector based drug delivery system for overcoming drug resistance
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
WO2020072519A8 (en) Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
WO2014052305A3 (en) Method for treating breast cancer using mitochondrial poisons that interfere with over-expressed mitochondrial proteins
HK1200354A1 (en) Combination therapy for chemoresistant cancers
ATE553189T1 (de) Immunokinasen
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration
WO2006039343A3 (en) Emmprin antagonists and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal